TN2009000189A1 - Tetrahydrocyclopenta [b] indole compounds as androgen receptor modulators - Google Patents

Tetrahydrocyclopenta [b] indole compounds as androgen receptor modulators

Info

Publication number
TN2009000189A1
TN2009000189A1 TNP2009000189A TN2009000189A TN2009000189A1 TN 2009000189 A1 TN2009000189 A1 TN 2009000189A1 TN P2009000189 A TNP2009000189 A TN P2009000189A TN 2009000189 A TN2009000189 A TN 2009000189A TN 2009000189 A1 TN2009000189 A1 TN 2009000189A1
Authority
TN
Tunisia
Prior art keywords
formula
tetrahydrocyclopenta
androgen receptor
receptor modulators
compound
Prior art date
Application number
TNP2009000189A
Other languages
English (en)
French (fr)
Inventor
Konstantinos Gavardinas
Jonathan Edward Green
Prabhakar Kondaji Jadhav
Donald Paul Matthews
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TN2009000189A1 publication Critical patent/TN2009000189A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
TNP2009000189A 2006-11-20 2009-05-15 Tetrahydrocyclopenta [b] indole compounds as androgen receptor modulators TN2009000189A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20
PCT/US2007/083745 WO2008063867A2 (en) 2006-11-20 2007-11-06 Tetrahydrocyclopenta[b] indole compounds as androgen receptor modulators

Publications (1)

Publication Number Publication Date
TN2009000189A1 true TN2009000189A1 (en) 2010-10-18

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000189A TN2009000189A1 (en) 2006-11-20 2009-05-15 Tetrahydrocyclopenta [b] indole compounds as androgen receptor modulators

Country Status (36)

Country Link
US (1) US7968587B2 (enExample)
EP (1) EP2094658B1 (enExample)
JP (1) JP5399259B2 (enExample)
KR (1) KR101121471B1 (enExample)
CN (1) CN101541749B (enExample)
AR (1) AR063559A1 (enExample)
AT (1) ATE538091T1 (enExample)
AU (1) AU2007324046B2 (enExample)
BR (1) BRPI0719092B8 (enExample)
CA (1) CA2670340C (enExample)
CL (1) CL2007003182A1 (enExample)
CO (1) CO6190513A2 (enExample)
CR (1) CR10802A (enExample)
CY (1) CY1112284T1 (enExample)
DK (1) DK2094658T3 (enExample)
EA (1) EA015627B1 (enExample)
EC (1) ECSP099350A (enExample)
ES (1) ES2376048T3 (enExample)
HR (1) HRP20120032T1 (enExample)
IL (1) IL198410A (enExample)
JO (1) JO2800B1 (enExample)
MA (1) MA31072B1 (enExample)
MX (1) MX2009005251A (enExample)
MY (1) MY154547A (enExample)
NO (1) NO342531B1 (enExample)
NZ (1) NZ576296A (enExample)
PE (1) PE20081161A1 (enExample)
PL (1) PL2094658T3 (enExample)
PT (1) PT2094658E (enExample)
RS (1) RS52191B (enExample)
SI (1) SI2094658T1 (enExample)
TN (1) TN2009000189A1 (enExample)
TW (1) TWI398438B (enExample)
UA (1) UA98777C2 (enExample)
WO (1) WO2008063867A2 (enExample)
ZA (1) ZA200903096B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX2010009162A (es) 2008-02-22 2010-12-21 Radius Health Inc Moduladores selectivos del receptor de androgeno.
HRP20120917T1 (hr) * 2008-05-16 2012-12-31 Eli Lilly & Company TETRAHIDROCIKLOPENTA[b]INDOLSKI MODULATORI ANDROGENOG RECEPTORA
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
MX338831B (es) 2010-02-04 2016-05-03 Radius Health Inc Moduladores selectivos de receptores de androgenos.
ME02474B (me) 2010-05-12 2017-02-20 Radius Health Inc Terapijski režimi
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
EP2621901B1 (en) 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
US20140113824A1 (en) 2011-05-10 2014-04-24 Bayer Intellectual Property Gmbh Bicyclic (thio)carbonylamidines
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
SMT202300072T1 (it) 2014-03-28 2023-05-12 Univ Duke Cancro della mammella mediante l'utilizzo di modulatori selettivi del recetiore degli estrogeni
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
RU2022108295A (ru) 2016-06-22 2022-04-06 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
CN117417263A (zh) 2017-01-05 2024-01-19 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
CN112423844B (zh) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
MA54946A (fr) 2019-02-12 2021-12-22 Radius Pharmaceuticals Inc Procédés et composés
CN115023225A (zh) * 2020-01-27 2022-09-06 伊尔根制药有限公司 用于治疗肾病的四氢环戊[b]吲哚化合物
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
ATE350036T1 (de) * 1999-10-14 2007-01-15 Kaken Pharma Co Ltd Tetrahydroquinolin-derivate
EP1423366A1 (en) 2001-08-09 2004-06-02 Eli Lilly And Company Cyclopenta b ! indole derivatives as spla2 inhibitors
DE10164564B4 (de) 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
BRPI0507657A (pt) * 2004-03-03 2007-07-10 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
US20090170923A1 (en) * 2004-11-22 2009-07-02 Kristjan Gudmundsson Hcv inhibitors
EP1824821A2 (en) 2004-11-23 2007-08-29 PTC Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
TW200640931A (en) 2005-02-17 2006-12-01 Wyeth Corp Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
JP5204650B2 (ja) 2005-06-24 2013-06-05 イーライ リリー アンド カンパニー アンドロゲン受容体調節物質として有用なテトラヒドロカルバゾール誘導体
WO2007047604A2 (en) 2005-10-18 2007-04-26 Elixir Pharmaceuticals, Inc. Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
HRP20120917T1 (hr) 2008-05-16 2012-12-31 Eli Lilly & Company TETRAHIDROCIKLOPENTA[b]INDOLSKI MODULATORI ANDROGENOG RECEPTORA

Also Published As

Publication number Publication date
RS52191B (sr) 2012-10-31
CN101541749A (zh) 2009-09-23
CL2007003182A1 (es) 2008-06-27
CY1112284T1 (el) 2015-12-09
ZA200903096B (en) 2010-07-28
NO342531B1 (no) 2018-06-11
MY154547A (en) 2015-06-30
ES2376048T3 (es) 2012-03-08
PE20081161A1 (es) 2008-08-15
US7968587B2 (en) 2011-06-28
NZ576296A (en) 2011-11-25
KR101121471B1 (ko) 2012-02-28
CN101541749B (zh) 2013-03-27
EP2094658B1 (en) 2011-12-21
KR20090082229A (ko) 2009-07-29
TW200827347A (en) 2008-07-01
PT2094658E (pt) 2012-02-22
ECSP099350A (es) 2009-06-30
CR10802A (es) 2009-07-13
EA015627B1 (ru) 2011-10-31
US20100069404A1 (en) 2010-03-18
IL198410A0 (en) 2010-02-17
JP5399259B2 (ja) 2014-01-29
CA2670340C (en) 2014-05-20
MX2009005251A (es) 2009-08-19
PL2094658T3 (pl) 2012-05-31
CO6190513A2 (es) 2010-08-19
DK2094658T3 (da) 2012-02-13
EP2094658A2 (en) 2009-09-02
AU2007324046A1 (en) 2008-05-29
ATE538091T1 (de) 2012-01-15
BRPI0719092A2 (pt) 2013-12-03
SI2094658T1 (sl) 2012-04-30
CA2670340A1 (en) 2008-05-29
HRP20120032T1 (hr) 2012-02-29
JP2010510231A (ja) 2010-04-02
WO2008063867A2 (en) 2008-05-29
BRPI0719092B1 (pt) 2020-08-18
WO2008063867A3 (en) 2008-07-31
HK1134089A1 (en) 2010-04-16
JO2800B1 (en) 2014-03-15
TWI398438B (zh) 2013-06-11
IL198410A (en) 2013-09-30
UA98777C2 (en) 2012-06-25
AR063559A1 (es) 2009-02-04
AU2007324046B2 (en) 2012-04-05
NO20092103L (no) 2009-05-28
EA200970500A1 (ru) 2009-10-30
BRPI0719092B8 (pt) 2021-05-25
MA31072B1 (fr) 2010-01-04

Similar Documents

Publication Publication Date Title
TN2009000189A1 (en) Tetrahydrocyclopenta [b] indole compounds as androgen receptor modulators
WO2009140448A8 (en) Tetrahydrocyclopenta[b]indole androgen receptor modulators
PL1891038T3 (pl) Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego
PL1902026T3 (pl) Pochodne tetrahydrokarbazolu użyteczne jako modulatory receptora androgenowego (SARM)
MX2009011816A (es) Derivados de piridina.
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
UA86621C2 (ru) Антагонисты рецептора глюкагона, их получение и терапевтическое применение
PL1957484T3 (pl) Antagoniści receptora glukagonu, wytwarzanie i zastosowanie w lecznictwie
TW200626158A (en) Naphthaline derivatives
WO2008004100A3 (en) Therapeutic compounds
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
IL206611A0 (en) Novel imidazolinylmethyl aryl sulfonamides
MX2010007928A (es) Imidazolinilmetil aril sulfonamidas novedosas.
DOP2009000117A (es) Compuestos de tetrahidrociclopenta[b]indol como moduladores del receptor de andrógenos
MX2010008019A (es) Nuevas imidazolinilmetil aril sulfonamidas.
UA90264C2 (ru) Три(цикло)замещенные амиды, фармацевтическая композиция, способы лечения и профилактики, способ получения соединения